bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S3 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
Authors: Buondonno Ilaria , Gazzano Elena , Jean Sae Rin , Audrito Valentina , Kopecka Joanna , Fanelli Marilù , Salaroglio Iris C. , Costamagna Costanzo , Roato Ilaria , Mungo Eleonora , Hattinger Claudia M. , Deaglio Silvia , Kelley Shana O. , Serra Massimo , Riganti Chiara
Published: April 2023

Effects of mitochondria-targeted doxorubicin in drug-sensitive Saos-2 cells and in their resistant variants, and in K7M2 cells
Supplementary Figure S2 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
Authors: Buondonno Ilaria , Gazzano Elena , Jean Sae Rin , Audrito Valentina , Kopecka Joanna , Fanelli Marilù , Salaroglio Iris C. , Costamagna Costanzo , Roato Ilaria , Mungo Eleonora , Hattinger Claudia M. , Deaglio Silvia , Kelley Shana O. , Serra Massimo , Riganti Chiara
Published: April 2023

Expression of Pgp and MRP1 in doxorubicin-sensitive and doxorubicin-resistant osteosarcoma cells
Table S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

Supplementary Table 2: List of all cell lines in the CCLE where sensitivity to SHP099 was evaluated in 2D. Lineage and genetic status of KRAS and BRAF are shown. Blank cells represent cell line data where genetic or screening data do not exist. Data depicted in Figure 1B are IC50 values. This table includes all sensitivity data based on both IC50 and Amax data.
Supplementary Table S1 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Authors: Moore Heather M. , Savage Heidi M. , O'Brien Carol , Zhou Wei , Sokol Ethan S. , Goldberg Michael E. , Metcalfe Ciara , Friedman Lori S. , Lackner Mark R. , Wilson Timothy R.
Published: April 2023

Supplementary Table S1: Summary of basic protein expression, PIK3CA mutations and response to taselisib (IC50) of a panel of 50 breast cancer cell lines.
Supplementary Figure S5 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Authors: Moore Heather M. , Savage Heidi M. , O'Brien Carol , Zhou Wei , Sokol Ethan S. , Goldberg Michael E. , Metcalfe Ciara , Friedman Lori S. , Lackner Mark R. , Wilson Timothy R.
Published: April 2023

Supplementary Figure S5: Taselisib-mediated induction of ER activity in PIK3CA-mutant breast cancer cells is dependent on ligand and ER function.
Supplementary Figure S4 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Authors: Moore Heather M. , Savage Heidi M. , O'Brien Carol , Zhou Wei , Sokol Ethan S. , Goldberg Michael E. , Metcalfe Ciara , Friedman Lori S. , Lackner Mark R. , Wilson Timothy R.
Published: April 2023

Supplementary Figure S4: Taselisib-mediated induction of ESR1 and hormone signaling is dependent on PIK3CA mutational status.
Supplementary Figure S1 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Authors: Moore Heather M. , Savage Heidi M. , O'Brien Carol , Zhou Wei , Sokol Ethan S. , Goldberg Michael E. , Metcalfe Ciara , Friedman Lori S. , Lackner Mark R. , Wilson Timothy R.
Published: April 2023

Supplementary Figure S1: Protein expression profile of a panel of breast cancer cell lines and the dose-dependent PI3K signaling response of PIK3CA-mutant cell lines to taselisib.
Ku et al_supplemental_methods from ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas
Authors: Ku Min-Chi , Edes Inan , Bendix Ivo , Pohlmann Andreas , Waiczies Helmar , Prozorovski Tim , Günther Martin , Martin Conrad , Pagès Gilles , Wolf Susanne A. , Kettenmann Helmut , Uckert Wolfgang , Niendorf Thoralf , Waiczies Sonia
Published: April 2023

Supplemental Methods
Supplementary Tables 1 through 4 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Authors: Guichard Sylvie M. , Curwen Jon , Bihani Teeru , D'Cruz Celina M. , Yates James W.T. , Grondine Michael , Howard Zoe , Davies Barry R. , Bigley Graham , Klinowska Teresa , Pike Kurt G. , Pass Martin , Chresta Christine M. , Polanska Urszula M. , McEwen Robert , Delpuech Oona , Green Stephen , Cosulich Sabina C.
Published: April 2023

Supplementary table 1: Biochemical and cellular activity of AZD2014. Supplementary table 2: Biochemical activity of AZD2014. Supplementary table 3: Anti proliferative activity of AZD2014 in a panel of ER+, endocrine resistant and LTED cell lines. Supplementary table 4: Activity of AZD2014 in a number of ER+ breast cancer in vivo models.
Figure S3 from Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
Authors: Shin Dong Hoon , Jo Jeong Yeon , Han Ji-Youn
Published: April 2023

Appearance of the tumors at the time of sacrifice.
Figure S2 from Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
Authors: Shin Dong Hoon , Jo Jeong Yeon , Han Ji-Youn
Published: April 2023

RT-PCR analysis of E.V. and SLC3A2-NRG1 gene expressed cells to check the fusion gene levels. Student''s t test, average {plus minus} SD; n=4, *, p<0.05.
Supplementary Figure 4 from Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Authors: Zoeller Jason J. , Vagodny Aleksandr , Taneja Krishan , Tan Benjamin Y. , O'Brien Neil , Slamon Dennis J. , Sampath Deepak , Leverson Joel D. , Bronson Roderick T. , Dillon Deborah A. , Brugge Joan S.
Published: April 2023

ABT-737 enhances the effectiveness of T-DM1 in vivo.
Supplemental Figure S4 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Authors: Whalen Kerry A. , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Alargova Rossitza , Au Yeung Tsun P. , Bazinet Patrick , Brockman Adam , DuPont Michelle M. , Oller Haley , Gifford James , Lemelin Charles-Andre , Lim Soo Patrick , Perino Samantha , Moreau Benoît , Sharma Gitanjali , Shinde Rajesh , Sweryda-Krawiec Beata , Bilodeau Mark T. , Wooster Richard
Published: April 2023

Body weight (BW) and health observations for efficacy studies
Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Authors: Whalen Kerry A. , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Alargova Rossitza , Au Yeung Tsun P. , Bazinet Patrick , Brockman Adam , DuPont Michelle M. , Oller Haley , Gifford James , Lemelin Charles-Andre , Lim Soo Patrick , Perino Samantha , Moreau Benoît , Sharma Gitanjali , Shinde Rajesh , Sweryda-Krawiec Beata , Bilodeau Mark T. , Wooster Richard
Published: April 2023

In vitro inhibition of proliferation of SCLC cells by PEN-221 or DM1
Supplemental Figure S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Authors: Whalen Kerry A. , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Alargova Rossitza , Au Yeung Tsun P. , Bazinet Patrick , Brockman Adam , DuPont Michelle M. , Oller Haley , Gifford James , Lemelin Charles-Andre , Lim Soo Patrick , Perino Samantha , Moreau Benoît , Sharma Gitanjali , Shinde Rajesh , Sweryda-Krawiec Beata , Bilodeau Mark T. , Wooster Richard
Published: April 2023

SSTR2 expression analysis in xenograft tissue
Figure S1 from Wedelolactone, an Anti-inflammatory Botanical, Interrupts c-Myc Oncogenic Signaling and Synergizes with Enzalutamide to Induce Apoptosis in Prostate Cancer Cells
Authors: Sarveswaran Sivalokanathan , Ghosh Ritisha , Parikh Rujul , Ghosh Jagadananda
Published: April 2023

Supplementary Figure 1-chemical structures of Wedelolactone and Enzalutamide.
Supplemental Figure 6 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Authors: Kietzman William B. , Graham Garrett T. , Ory Virginie , Sharif Ghada M. , Kushner Max H. , Gallanis Gregory T. , Kallakury Bhaskar , Wellstein Anton , Riegel Anna T.
Published: April 2023

Palbociclib's transcriptomic effects on tumors
Supplementary Video S1A from Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
Authors: Scott Gary K. , Yau Christina , Becker Beatrice C. , Khateeb Sana , Mahoney Sophia , Jensen Martin Borch , Hann Byron , Cowen Bryan J. , Pegan Scott D. , Benz Christopher C.
Published: April 2023

Geotaxis comparison of control and N-PPG treated flies
Supplement Figure 3 from Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
Authors: Scott Gary K. , Yau Christina , Becker Beatrice C. , Khateeb Sana , Mahoney Sophia , Jensen Martin Borch , Hann Byron , Cowen Bryan J. , Pegan Scott D. , Benz Christopher C.
Published: April 2023

Supplement Figure 3. Confocal images of control and N-PPG treated ZR-75-1 cell cultures show absence of mitochondrial membrane recruitment of PINK/PARKIN complex (A), despite positive induction of mitochondrial GRP-75 import (B), within 24 h of N-PPG treatment.
Supplement Figure 1 from Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
Authors: Scott Gary K. , Yau Christina , Becker Beatrice C. , Khateeb Sana , Mahoney Sophia , Jensen Martin Borch , Hann Byron , Cowen Bryan J. , Pegan Scott D. , Benz Christopher C.
Published: April 2023

Supplement Figure 1. Mitochondria isolated from ZR-75-1 cells and assayed for PRODH activity assessed by either P5C production (A) or substrate inducing NADH formation (B), with use of NADH bioassay to compare PRODH inhibitor effects (C, D).
Supplementary Figures S1-S6 and Tables S1-S2 from SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer
Authors: Joshi Shweta , Singh Alok R. , Liu Kevin X. , Pham Timothy V. , Zulcic Muamera , Skola Dylan , Chun Hyun Bae , Glass Christopher K. , Morales Guillermo A. , Garlich Joseph R. , Durden Donald L.
Published: April 2023

Supplementary Fig. S1 shows JQ1 blocks IL4 induced CD206 expression. Supplementary Fig. S2 shows Differentially expressed genes in LPS-stimulated or IL4 stimulated BMDMs. Supplementary Fig. S3 shows Effect of JQ1 on LLC tumor growth. Supplementary Fig. S4 shows SF1126 blocks tumor growth and immunosuppressive macrophage polarization. Supplementary Fig. S5 shows JQ1 and SF2523 reduce tumor growth due to its effect on macrophages. Supplementary Fig. S6 shows SF2523 inhibits B16 tumor metastasis. Supplementary Table S1 shows Primers used for ChIP analysis. Supplementary Table S2 shows Contingency tables representing the effects on the number of shared over or under expressed genes of different exposures.
Supplementary Figure 6 from Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells
Authors: Anantharajan Jothi , Zhou Hengbo , Zhang Lingdi , Hotz Taylor , Vincent Melanie Y. , Blevins Melanie A. , Jansson Anna E. , Kuan John Wee Liang , Ng Elizabeth Yihui , Yeo Yee Khoon , Baburajendran Nithya , Lin Grace , Hung Alvin W. , Joy Joma , Patnaik Samarjit , Marugan Juan , Rudra Pratyaydipta , Ghosh Debashis , Hill Jeffrey , Keller Thomas H. , Zhao Rui , Ford Heide L. , Kang CongBao
Published: April 2023

Cellular activity of 9987 in HCC4006 cells. HCC4006 cells were treated with 9987 at 5 or 10 mM and the efficacy of 9987 was tested on overall growth, colony formation, motility, and invasion.
Supplementary Data from SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer
Authors: Joshi Shweta , Singh Alok R. , Liu Kevin X. , Pham Timothy V. , Zulcic Muamera , Skola Dylan , Chun Hyun Bae , Glass Christopher K. , Morales Guillermo A. , Garlich Joseph R. , Durden Donald L.
Published: April 2023

File contains Supplementary Methods and References
Supplementary Figure 5 from Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells
Authors: Anantharajan Jothi , Zhou Hengbo , Zhang Lingdi , Hotz Taylor , Vincent Melanie Y. , Blevins Melanie A. , Jansson Anna E. , Kuan John Wee Liang , Ng Elizabeth Yihui , Yeo Yee Khoon , Baburajendran Nithya , Lin Grace , Hung Alvin W. , Joy Joma , Patnaik Samarjit , Marugan Juan , Rudra Pratyaydipta , Ghosh Debashis , Hill Jeffrey , Keller Thomas H. , Zhao Rui , Ford Heide L. , Kang CongBao
Published: April 2023

Eya2 binding to Six1 is critical for its ability to mediate numerous phenotypes in Calu-6 lung cancer cells.
Supplementary methods and figures from Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Authors: Velmurugan Ramraj , Challa Dilip K. , Ram Sripad , Ober Raimund J. , Ward E. Sally
Published: April 2023

Document containing supplementary methods, supplementary figure legends for supplementary movies and figures; Figure S1. Harvesting efficiency of cancer cells in macrophage:cancer cell co-cultures; Figure S2. Macrophage-mediated reduction of opsonized target cell numbers occurs in media optimized for cancer cell growth. J774A.1 or RAW264; Figure S3. Macrophage-mediated killing of opsonized target cells is contact-dependent. Different combinations of 1Ã—105 RAW264; Figure S4. Macrophage-mediated killing of opsonized target cells occurs in the presence of the reactive oxygen species scavenger, edaravone; Figure S5. Representative images of conjugates formed between two macrophage cell lines and three cancer cell lines; Figure S6. Human macrophages perform both phagocytosis and trogocytosis of antibody-opsonized target cells and reduce cancer cell numbers; Figure S7. Effect of effector:target ratio on WCP activity; Figure S8. Macrophages induce apoptosis in opsonized cancer cells; Figure S9. Trogosomes are rapidly targeted to lysosomes; Figure S10. The macrophage:cancer cell synapse is similar for both RAW264.7 and J774A.1 macrophages; Figure S11. J774A.1 and RAW264.7 macrophages express all of the mouse FcÎ³Rs.; Figure S12. Breast cancer cell lines and B cells exhibit different capping behavior in response to antibody opsonization; Figure S13. Engineered antibodies with enhanced FcÎ³R binding affinities do not increase WCP activity during a 3 hour incubation; Figure S14. The inhibitory effect of IVIG on trogocytosis is not due to the effect of aggregated IgG or IgM; Figure S15. Human macrophage (MÏ•) effectors can deplete cancer cells in the presence of IVIG and antibodies with enhanced binding affinities for FcÎ³Rs.
Supplementary Figure 3 from Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells
Authors: Anantharajan Jothi , Zhou Hengbo , Zhang Lingdi , Hotz Taylor , Vincent Melanie Y. , Blevins Melanie A. , Jansson Anna E. , Kuan John Wee Liang , Ng Elizabeth Yihui , Yeo Yee Khoon , Baburajendran Nithya , Lin Grace , Hung Alvin W. , Joy Joma , Patnaik Samarjit , Marugan Juan , Rudra Pratyaydipta , Ghosh Debashis , Hill Jeffrey , Keller Thomas H. , Zhao Rui , Ford Heide L. , Kang CongBao
Published: April 2023

Compound inhibition of different Eya proteins and Eya mutants.
Supplementary Figure 2 from Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells
Authors: Anantharajan Jothi , Zhou Hengbo , Zhang Lingdi , Hotz Taylor , Vincent Melanie Y. , Blevins Melanie A. , Jansson Anna E. , Kuan John Wee Liang , Ng Elizabeth Yihui , Yeo Yee Khoon , Baburajendran Nithya , Lin Grace , Hung Alvin W. , Joy Joma , Patnaik Samarjit , Marugan Juan , Rudra Pratyaydipta , Ghosh Debashis , Hill Jeffrey , Keller Thomas H. , Zhao Rui , Ford Heide L. , Kang CongBao
Published: April 2023

Crystal structure of Eya2 ED-9987 complex shows three Eya2 ED-9987 complexes in one asymmetric unit, with the 9987-binding pocket in the Eya2-9987 crystal structure overlaps with the binding pocket predicted from mutagenesis studies.
Supplementary Figure 1 from Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells
Authors: Anantharajan Jothi , Zhou Hengbo , Zhang Lingdi , Hotz Taylor , Vincent Melanie Y. , Blevins Melanie A. , Jansson Anna E. , Kuan John Wee Liang , Ng Elizabeth Yihui , Yeo Yee Khoon , Baburajendran Nithya , Lin Grace , Hung Alvin W. , Joy Joma , Patnaik Samarjit , Marugan Juan , Rudra Pratyaydipta , Ghosh Debashis , Hill Jeffrey , Keller Thomas H. , Zhao Rui , Ford Heide L. , Kang CongBao
Published: April 2023

Alphascreen monitoring of the Six1/Eya2 interaction demonstrates that compound 9987 has no effect on this interaction.
Movie S1 from Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Authors: Velmurugan Ramraj , Challa Dilip K. , Ram Sripad , Ober Raimund J. , Ward E. Sally
Published: April 2023

Two-color live cell imaging of a J774A.1 macrophage phagocytosing MDA-MB-453 cancer cells. Macrophages with surface-labeled CD45 (green) engulf three trastuzumab-opsonized MDA-MB-453 cells (red). Time is indicated at the top left in minutes:seconds format. The movie plays at a speed of 340x real-time
Supplementary Table 1 from The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance
Authors: Woolbright Benjamin L. , Choudhary Dharamainder , Mikhalyuk Andrew , Trammel Cassandra , Shanmugam Sambantham , Abbott Erika , Pilbeam Carol C. , Taylor John A.
Published: April 2023

Combination Index
Figure S2. CyTOF-SPADE analysis shows upregulation of p53 and Bax proteins by treatment with PLK1 inhibitor volasertib (BI6727) in primary B-ALL. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
Authors: Kannan Sankaranarayanan , Aitken Marisa J.L. , Herbrich Shelley M. , Golfman Leonard S. , Hall Mandy G. , Mak Duncan H. , Burks Jared K. , Song Guangchun , Konopleva Marina , Mullighan Charles G. , Chandra Joya , Zweidler-McKay Patrick A.
Published: April 2023

Primary Ph-like B-ALL (Pt.B1) was treated with PLK1 inhibitor volasertib (100 nm) for 30 min. Cells were harvested and subjected to single cell time of flight mass cytometry (CyTOF) and analyzed using the Spanning Tree Progression of Density Normalized Events (SPADE) algorithm as previously described (ref). SPADE analysis shows an increased median level expression of the p53 protein and the pro-apoptotic Bax protein in cells subjected to PLK1 inhibition.
Figure S2 from The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance
Authors: Woolbright Benjamin L. , Choudhary Dharamainder , Mikhalyuk Andrew , Trammel Cassandra , Shanmugam Sambantham , Abbott Erika , Pilbeam Carol C. , Taylor John A.
Published: April 2023

Proliferation HTB-5 and HTB-9 with cisplatin, DCA or both
Figure S1 from The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance
Authors: Woolbright Benjamin L. , Choudhary Dharamainder , Mikhalyuk Andrew , Trammel Cassandra , Shanmugam Sambantham , Abbott Erika , Pilbeam Carol C. , Taylor John A.
Published: April 2023

Relative expression of HIF-1a and PPARa
Supplementary Figure 1: Early cutaneous invasion of WM35 melanoma cells in full-thickness human skin equivalents results in disruption of basement membrane component type IV collagen from A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion
Authors: Hill David S. , Robinson Neil D.P. , Caley Matthew P. , Chen Mei , O'Toole Edel A. , Armstrong Jane L. , Przyborski Stefan , Lovat Penny E.
Published: April 2023

supplementary figure 1
Supplementary Table 1 - Cell line information from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma
Authors: Chornenkyy Yevgen , Agnihotri Sameer , Yu Man , Buczkowicz Pawel , Rakopoulos Patricia , Golbourn Brian , Garzia Livia , Siddaway Robert , Leung Stephie , Rutka James T. , Taylor Michael D. , Dirks Peter B. , Hawkins Cynthia
Published: April 2023

Cell line information
Supplementary Figure 3 - Niraparib treatment increases DNA damage and decreases proliferation. from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma
Authors: Chornenkyy Yevgen , Agnihotri Sameer , Yu Man , Buczkowicz Pawel , Rakopoulos Patricia , Golbourn Brian , Garzia Livia , Siddaway Robert , Leung Stephie , Rutka James T. , Taylor Michael D. , Dirks Peter B. , Hawkins Cynthia
Published: April 2023

A and C, Representative immunofluorescence staining for γH2AX and ki67 in SJG2, SF188, KNS42, and DIPG58 cells after a 24 hour incubation with either DMSO vehicle (V) or 5 μM Niraparib (N). DAPI was used as a nuclear counterstain. B and D, Quantification of γH2AX and ki67 in SJG2, SF188, KNS42, and DIPG58 cells. γH2AX images were taken at 63X magnification, scale bar 12 μm, ki67 images were taken at 25X magnification, scale bar 30 μm. **, ***, **** Denotes significance of p<0.01, p<0.001, p<0.0001, respectively. Error bars represent standard error of the mean.
Supplementary Figure 2 - Cell viability assay for pediatric brain tumour lines exposed to the indicated concentrations of Veliparib, Olaparib, or Niraparib. from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma
Authors: Chornenkyy Yevgen , Agnihotri Sameer , Yu Man , Buczkowicz Pawel , Rakopoulos Patricia , Golbourn Brian , Garzia Livia , Siddaway Robert , Leung Stephie , Rutka James T. , Taylor Michael D. , Dirks Peter B. , Hawkins Cynthia
Published: April 2023

A, MTT cell viability relative absorbance values across multiple cell lines after a 7-day incubation with Veliparib, Olaparib, or Niraparib. Boxes with an asterisk denote that an indicated concentration of PARP inhibitor significantly reduced cell viability relative vehicle treated cells. B, MTT cell viability heat map with numerical values. C, Linear regression analysis between PARP1 protein levels, relative to GAPDH, across all cell lines vs. IC50 values calculated from MTT viability assay on day 7. D, Linear regression analysis between PARP1 activity levels, relative to GAPDH, across all cell lines vs. IC50 values calculated from MTT viability assay on day 7. E, Different exposure of PARP1 Western blot in SJG2, SF188, 462, and 626 cells demonstrating variable PARP1 protein expression. *, **, ***, **** Denotes significance of p<0.05, p<0.01, p<0.001, p<0.0001, respectively. Error bars represent SEM.
Supplementary Table 1 from Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
Authors: Kang Chan Woo , Jang Kang Won , Sohn Jinyoung , Kim Sung-Moo , Pyo Kyoung-Ho , Kim Hwan , Yun Mi Ran , Kang Han Na , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Paik Soonmyung , Kim Dae Joon , Kim Joo Hang , Cho Byoung Chul
Published: April 2023

Supplementary Table 1. Docking score of dovitinib, vandetanib, and sunitinib against RET kinase.
Supplementary Figure 1 - PARP1 protein is expressed in pHGA and DIPG patient samples from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma
Authors: Chornenkyy Yevgen , Agnihotri Sameer , Yu Man , Buczkowicz Pawel , Rakopoulos Patricia , Golbourn Brian , Garzia Livia , Siddaway Robert , Leung Stephie , Rutka James T. , Taylor Michael D. , Dirks Peter B. , Hawkins Cynthia
Published: April 2023

A, Representative immunohistochemical staining for PARP1 in pHGA and DIPG patient samples. Pictures were taken at 10X magnification. Scale bar 100 μm.
Supplementary Figures S1-S11 from Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab
Authors: Oashi Ayano , Yasuda Hiroyuki , Kobayashi Keigo , Tani Tetsuo , Hamamoto Junko , Masuzawa Keita , Manabe Tadashi , Terai Hideki , Ikemura Shinnosuke , Kawada Ichiro , Naoki Katsuhiko , Soejima Kenzo
Published: April 2023

Figure S1 Synergistic efficacy of afatinib and cetuximab combination therapy Figure S2 Efficacy of EGFR-TKIs and cetuximab combination therapy Figure S3 Effect of EGFR tyrosine kinase inhibitors on EGFR monomer dimer equilibrium Figure S4 Dimerization of EGFR by EGF Figure S5 Proliferation of Ba/F3 cells with indicated EGFR genotypes in vitro Figure S6 Detection of monomer or dimer of EGFR in NIH-3T3 cells by immunoblotting Figure S7 Synergistic efficacy of dacomitinib and cetuximab combination therapy Figure S8 Monomer preference of dacomitinib Figure S9 Effect of the combination therapy in vivo model Figure S10 Evaluation of the cell surface EGFR expression level after drug treatment by flow cytometric analysis Figure S11 Efficacy of the afatinib and cetuximab combination therapy in osimertinib resistant cell lines
Supplementary Figure 1 from Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
Authors: Kang Chan Woo , Jang Kang Won , Sohn Jinyoung , Kim Sung-Moo , Pyo Kyoung-Ho , Kim Hwan , Yun Mi Ran , Kang Han Na , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Paik Soonmyung , Kim Dae Joon , Kim Joo Hang , Cho Byoung Chul
Published: April 2023

Supplementary Figure 1. Supplementary Figure S1. Dovitinib inhibits RET kinase and its downstream signaling in lung cancer cells harboring RET rearrangement A, Western blot analysis of indicated markers in LC-2/ad cells after treated with indicated dose of dovitinib for 4hr. B. Western blot analysis to measure the levels of total FGFR3, FLT3, RET, and KIT upon siRNA treatment in LC-2/ad cell line. Cells were transfected with indicated siRNA for 48hr.
Supplementary Table S1-S2; Supplementary Figures S1-S3 from Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition
Authors: Wiegmans Adrian P. , Yap Pei-Yi , Ward Ambber , Lim Yi Chieh , Khanna Kum Kum
Published: April 2023

Supp. Table 1 is an IC50 calculation of each individual HDACi (SAHA, VPA, ROMI) and PARPi (ABT-888) against the four TNBC cell lines MDA-MB-231, MDA-MB-436, HCC1937(MUT) and HCC1937(RECON). Supp. Table 2 displays the combination index of the HDACi at IC20 with 2.5uM PARPi for each of the 4 cell lines described in table 1. <1 synergy, >1 antagonism. Supp Fig 1. Is a DRGFP analysis of homologous recombination activity in to repair a GFP construct in the presence of the HDACi. We confirmed with immunofluorescence of RAD51 and marker of double strand breaks gammaH2Ax. Supp Fig 2. A) Is fluorescence microscopy displaying polyploidy in response to HDACi ROMI. B and C) Expression analysis of a set of DNA repair genes in response to HDACi (SAHA, VPA and ROMI). D) Protein expression analysis correlating with gene expression response. E) Validation of RAD51, BARD1 and FANCD2 depletion by siRNA. F-H) Cell cycle profile of MDA-MB-231 response to genetic depletion in the presence of HDACi (VPA)and PARPi (ABT-888). Supp. Fig 3. Optical and fluorescence microscopy of cells treated with combination ROMI and ABT-888.
Table S2 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

The list of miRNAs pulled down by CCAT1 sense and antisense strand in our RNA pulldown assay.
AC0010 supplementary Figure 2 from AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Authors: Xu Xiao , Mao Long , Xu Wanhong , Tang Wei , Zhang Xiaoying , Xi Biao , Xu Rongda , Fang Xin , Liu Jia , Fang Ce , Zhao Li , Wang Xiaobo , Jiang Ji , Hu Pei , Zhao Hongyun , Zhang Li
Published: April 2023

AC0010 Supplementary Figure 2. AC0010 kinase profiling
Figure S2 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

CCAT1 expression at different metastatic sites
Figure S1 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

Immunofluorescence staining for CCAT1 in PCa cells
Supplemental Figures 1 - 10 from eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Authors: Kong Tim , Xue Yibo , Cencic Regina , Zhu Xianbing , Monast Anie , Fu Zheng , Pilon Virginie , Sangwan Veena , Guiot Marie-Christine , Foulkes William D. , Porco John A. , Park Morag , Pelletier Jerry , Huang Sidong
Published: April 2023

Supplemental Figure 1 shows validation of cyclin E and CDK4 signals with RNAi. Supplemental Figure 2 shows that cyclin D1 dictates response to palbociclib and is limiting in the formation of CDK4/6-Cyclin D1 complexes in ER-positive breast cancer. Supplemental Figure 3 shows that rocaglates preferentially suppresses protein expression of cyclin D1, CDK4, and cyclin E1. Supplemental Figure 4 shows synergism between a second CDK4/6 inhibitor, Abemaciclib, and CR-1-31-B. Supplemental Figure 5 shows functional cell cycle effects of palbociclib and/or CR-1-31-B treatment in ER-positive breast cancer. Supplemental Figure 6 shows sensitivity of KRAS-mutant non-small cell lung cancers to palbociclib and CR-1-31-B. Supplemental Figure 7 shows functional cell cycle effects of palbociclib and/or CR-1-31-B treatment in NSCLC. Supplemental Figure 8 shows weights of subcutaneous xenografted NSG mice treated with palbociclib, CR-1-31-B, or their combination. Supplemental Figure 9 shows colony formation panel of palbociclib-resistant MCF-7 clones. Supplemental Figure 10 shows cell viability assay of CR-1-31-B response.
Supplementary Figure S6 from Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Authors: Zhang Lu , Riley-Gillis Bridget , Vijay Priyanka , Shen Yu
Published: April 2023

CUL2 and CRBN expression are associated with VHL or CRBN based PROTAC sensitivity, respectively.
Supplementary Figure S5 from Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Authors: Zhang Lu , Riley-Gillis Bridget , Vijay Priyanka , Shen Yu
Published: April 2023

mRNA expression and genetic alterations of CUL2 and CRBN in the TCGA dataset.
Supplementary Figure S4 from Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Authors: Zhang Lu , Riley-Gillis Bridget , Vijay Priyanka , Shen Yu
Published: April 2023

. RNA sequencing results in parental and resistant cells
Supplementary Figure S3 from Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Authors: Zhang Lu , Riley-Gillis Bridget , Vijay Priyanka , Shen Yu
Published: April 2023

Copy loss and of CUL2 or CRBN in resistant and Sanger sequencing at CUL2 loci.
Supplementary Figure 4 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Authors: Works Melissa , Soni Neha , Hauskins Collin , Sierra Catherine , Baturevych Alex , Jones Jon C. , Curtis Wendy , Carlson Patrick , Johnstone Timothy G. , Kugler David , Hause Ronald J. , Jiang Yue , Wimberly Lindsey , Clouser Christopher R. , Jessup Heidi K. , Sather Blythe , Salmon Ruth A. , Ports Michael O.
Published: April 2023

Supplementary Figure 4 shows the effects of lenalidomide on CD27, CCR7, CD45RA, and CAR positivity.
Supplementary Figure 3 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Authors: Works Melissa , Soni Neha , Hauskins Collin , Sierra Catherine , Baturevych Alex , Jones Jon C. , Curtis Wendy , Carlson Patrick , Johnstone Timothy G. , Kugler David , Hause Ronald J. , Jiang Yue , Wimberly Lindsey , Clouser Christopher R. , Jessup Heidi K. , Sather Blythe , Salmon Ruth A. , Ports Michael O.
Published: April 2023

Supplementary Figure 3 shows the effect of lenalidomide on cytokine production by anti-BCMA CAR T cells stimulated with BCMA beads for 24 hours.
Supplementary Figure 2 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Authors: Works Melissa , Soni Neha , Hauskins Collin , Sierra Catherine , Baturevych Alex , Jones Jon C. , Curtis Wendy , Carlson Patrick , Johnstone Timothy G. , Kugler David , Hause Ronald J. , Jiang Yue , Wimberly Lindsey , Clouser Christopher R. , Jessup Heidi K. , Sather Blythe , Salmon Ruth A. , Ports Michael O.
Published: April 2023

Supplementary Figure 2 shows the effect of lenalidomide on BCMA expression of the cell lines used in the experiments in this manuscript.
Supplementary information from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Authors: Watanabe Miyano Saori , Yamamoto Yuji , Kodama Kotaro , Miyajima Yukiko , Mikamoto Masaki , Nakagawa Takayuki , Kuramochi Hiroko , Funasaka Setsuo , Nagao Satoshi , Sugi Naoko Hata , Okamoto Kiyoshi , Minoshima Yukinori , Nakatani Yusuke , Karoji Yuki , Ohashi Isao , Yamane Yoshinobu , Okada Toshimi , Matsushima Tomohiro , Matsui Junji , Iwata Masao , Uenaka Toshimitsu , Tsuruoka Akihiko
Published: April 2023

Supplementary Table legends and Supplementary Figure legends.
Supplementary Table S2 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Authors: Watanabe Miyano Saori , Yamamoto Yuji , Kodama Kotaro , Miyajima Yukiko , Mikamoto Masaki , Nakagawa Takayuki , Kuramochi Hiroko , Funasaka Setsuo , Nagao Satoshi , Sugi Naoko Hata , Okamoto Kiyoshi , Minoshima Yukinori , Nakatani Yusuke , Karoji Yuki , Ohashi Isao , Yamane Yoshinobu , Okada Toshimi , Matsushima Tomohiro , Matsui Junji , Iwata Masao , Uenaka Toshimitsu , Tsuruoka Akihiko
Published: April 2023

IC50 values for growth inhibition of various cancer cell lines by E7090.
Supplementary Figure 2 from A Novel Fully Human Antibody targeting Extracellular Domain of PSMA Inhibits Tumor Growth in Prostate Cancer
Authors: Wu Jieheng , Han Donghui , Shi Shengjia , Zhang Qiang , Zheng Guoxu , Wei Ming , Han Yueheng , Li Guodong , Yang Fa , Jiao Dian , Xie Pin , Zhang Lingling , Yang An-Gang , Zhao Aizhi , Qin Weijun , Wen Weihong
Published: April 2023

(S2A) Competitive binding assay to examine the binding specificity of PSMAb. Different amount of PSMA protein was incubated with PSMAb before it was applied for the incubation with PSMA positive C4-2 cells and examined by flow cytometry. (S2B) DSC assay to examine the thermostability of PSMAb. Dialyzed PSMAb was diluted to 0.9 mg/mL and analyzed using VP-DSC capillary cell microcalorimeter.
Supplementary Figure S5 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Authors: Watanabe Miyano Saori , Yamamoto Yuji , Kodama Kotaro , Miyajima Yukiko , Mikamoto Masaki , Nakagawa Takayuki , Kuramochi Hiroko , Funasaka Setsuo , Nagao Satoshi , Sugi Naoko Hata , Okamoto Kiyoshi , Minoshima Yukinori , Nakatani Yusuke , Karoji Yuki , Ohashi Isao , Yamane Yoshinobu , Okada Toshimi , Matsushima Tomohiro , Matsui Junji , Iwata Masao , Uenaka Toshimitsu , Tsuruoka Akihiko
Published: April 2023

Western blot analysis of FGFR1 in human lung cancer cell lines harboring FGFR1 amplifications.
Supplementary Figure S4 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Authors: Watanabe Miyano Saori , Yamamoto Yuji , Kodama Kotaro , Miyajima Yukiko , Mikamoto Masaki , Nakagawa Takayuki , Kuramochi Hiroko , Funasaka Setsuo , Nagao Satoshi , Sugi Naoko Hata , Okamoto Kiyoshi , Minoshima Yukinori , Nakatani Yusuke , Karoji Yuki , Ohashi Isao , Yamane Yoshinobu , Okada Toshimi , Matsushima Tomohiro , Matsui Junji , Iwata Masao , Uenaka Toshimitsu , Tsuruoka Akihiko
Published: April 2023

siRNA knockdown experiment in 4T1 cells indicating that growth of 4T1 breast cancer cells depends on FGFR2 and FGFR3.
Supplementary Figure S3 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Authors: Watanabe Miyano Saori , Yamamoto Yuji , Kodama Kotaro , Miyajima Yukiko , Mikamoto Masaki , Nakagawa Takayuki , Kuramochi Hiroko , Funasaka Setsuo , Nagao Satoshi , Sugi Naoko Hata , Okamoto Kiyoshi , Minoshima Yukinori , Nakatani Yusuke , Karoji Yuki , Ohashi Isao , Yamane Yoshinobu , Okada Toshimi , Matsushima Tomohiro , Matsui Junji , Iwata Masao , Uenaka Toshimitsu , Tsuruoka Akihiko
Published: April 2023

Western blot analysis of phospho-FGFR in SNU-16 tumors at the indicated times after treatment with the indicated concentrations of E7090. See also Figure 3D.
Figure S2 from PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects
Authors: Rompré-Brodeur Alexis , Shinde-Jadhav Surashri , Ayoub Mina , Piccirillo Ciriaco A. , Seuntjens Jan , Brimo Fadi , Mansure Jose Joao , Kassouf Wassim
Published: April 2023

Flow cytometry gating strategy
Supplementary Table S2 from Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing
Authors: Cornillie Jasmien , Wozniak Agnieszka , Li Haifu , Wang Yannick , Boeckx Bram , Gebreyohannes Yemarshet K. , Wellens Jasmien , Vanleeuw Ulla , Hompes Daphne , Stas Marguerite , Sinnaeve Friedl , Wafa Hazem , Lambrechts Diether , Debiec-Rychter Maria , Sciot Raf , Schöffski Patrick
Published: April 2023

Intraclass correlation coefficients of outcome parameters of three different in vivo experiments using three different PDX models, exploring the degree of similarity between two tumors engrafted in the same mouse (data from ref. 18).
Supplementary Table 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Authors: Lu Hengyu , Liu Chen , Velazquez Roberto , Wang Hongyun , Dunkl Lukas Manuel , Kazic-Legueux Malika , Haberkorn Anne , Billy Eric , Manchado Eusebio , Brachmann Saskia M. , Moody Susan E. , Engelman Jeffrey A. , Hammerman Peter S. , Caponigro Giordano , Mohseni Morvarid , Hao Huai-Xiang
Published: April 2023

Quantification of p-MEK and tubulin levels and percentages of p-MEK reduction in the MEKi combination group normalized to tubulin in all cell lines tested.
Supplementary Table S1 from Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing
Authors: Cornillie Jasmien , Wozniak Agnieszka , Li Haifu , Wang Yannick , Boeckx Bram , Gebreyohannes Yemarshet K. , Wellens Jasmien , Vanleeuw Ulla , Hompes Daphne , Stas Marguerite , Sinnaeve Friedl , Wafa Hazem , Lambrechts Diether , Debiec-Rychter Maria , Sciot Raf , Schöffski Patrick
Published: April 2023

Detailed characterization of established STS PDX models.
Supplementary Figure 5 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Authors: Lu Hengyu , Liu Chen , Velazquez Roberto , Wang Hongyun , Dunkl Lukas Manuel , Kazic-Legueux Malika , Haberkorn Anne , Billy Eric , Manchado Eusebio , Brachmann Saskia M. , Moody Susan E. , Engelman Jeffrey A. , Hammerman Peter S. , Caponigro Giordano , Mohseni Morvarid , Hao Huai-Xiang
Published: April 2023

Changes in phospho-SHP2 levels following MEKi treatment in studied KRAS mutant lines.
Supplementary Figure 2 from The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells
Authors: Bergès Raphaël , Tchoghandjian Aurélie , Honoré Stéphane , Estève Marie-Anne , Figarella-Branger Dominique , Bachmann Felix , Lane Heidi A. , Braguer Diane
Published: April 2023

Modulation of EB1 expression in GBM6 cells using siRNA or shRNA against EB1
Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Authors: Lu Hengyu , Liu Chen , Velazquez Roberto , Wang Hongyun , Dunkl Lukas Manuel , Kazic-Legueux Malika , Haberkorn Anne , Billy Eric , Manchado Eusebio , Brachmann Saskia M. , Moody Susan E. , Engelman Jeffrey A. , Hammerman Peter S. , Caponigro Giordano , Mohseni Morvarid , Hao Huai-Xiang
Published: April 2023

Validation of HRAS/NRAS double knock-out clones and the contribution of mutant KRAS to the feedback activation in NCI-H358 and MIA PaCa-2.
Assessment of Therapeutic synergy with FTV method from Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity
Authors: Garofalo Mariangela , Iovine Barbara , Kuryk Lukasz , Capasso Cristian , Hirvinen Mari , Vitale Andrea , Yliperttula Marjo , Bevilacqua Maria Assunta , Cerullo Vincenzo
Published: April 2023

The assessment of therapeutic synergy was calculated with FTV method. Observed FTV (mean tumor volume experimental)/(mean tumor volume control). Expected FTV (Mean FTV of Carnosine6K) x (Mean FTV of virus). A ratio>1 indicates a synergistic effect, and a ratio<1 indicates a less than additive effect.
Supplementary Figure 6 - Immunopeptidome prediction of human CAIX. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Authors: Ziffels Barbara , Stringhini Marco , Probst Philipp , Fugmann Tim , Sturm Theo , Neri Dario
Published: April 2023

The prediction revealed more than 350 9-12mers potentially binding to the murine MHC class I alleles H-2Kd, H-2Dd and H-2Ld, leading to further immunopeptidome analysis of CT26 cells stably transfected with human CAIX.
Supplementary Figure 4 - DNA and amino acid sequences of XE-mTNF, XE-hIL2, XE-mIFNa2 and XE-mIL12. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Authors: Ziffels Barbara , Stringhini Marco , Probst Philipp , Fugmann Tim , Sturm Theo , Neri Dario
Published: April 2023

Colour code identification of the respective DNA and amino acid sequences is used as displayed in the respective headline.
Supplementary Table 1 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Authors: Couëtoux du Tertre Mathilde , Marques Maud , Tremblay Lise , Bouchard Nicole , Diaconescu Razvan , Blais Normand , Couture Christian , Pelsser Vincent , Wang Hangjun , Higenell Valerie , Izzi Luisa , Gambaro Karen , Hoffert Cyrla , Srivastava Archana , Spatz Alan , Rousseau Caroline , McNamara Suzan , Cohen Victor , Batist Gerald , Agulnik Jason
Published: April 2023

Best overall response and response rate
Supplementary Figure 2 - In vitro characterization of and therapy study with XE-mIL12. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Authors: Ziffels Barbara , Stringhini Marco , Probst Philipp , Fugmann Tim , Sturm Theo , Neri Dario
Published: April 2023

a) cloning scheme of XE-mIL12. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BALB/c mice bearing CT26 tumors transfected with human CAIX received three injections every 72 hours of either PBS as control or 12 Âµg of XE-mIL12. Statistical significance towards PBS control group is shown on day 19, *p<0.05. g) Body weight change during the treatment phase.
Supplementary Figure 1 - Ex vivo immunofluorescence analysis of tumor and organ sections. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Authors: Ziffels Barbara , Stringhini Marco , Probst Philipp , Fugmann Tim , Sturm Theo , Neri Dario
Published: April 2023

BALB/c mice bearing CT26 wildtype tumors (a, c) or CT26 tumors transfected with human CAIX (b) received one injection of 150 Âµg FITC-labelled IgG(XE114) (a) or 150 Âµg FITC-labelled IgG(KSF) (b, c) and were sacrificed 24h later. Binding of IgG(KSF) or IgG(XE114) was detected in green using an anti-FITC antibody and an AF488 labelled secondary antibody while blood vessels were stained in red using an anti-CD31 antibody and an AF594 labelled secondary antibody. Tu=tumor, St=stomach, In=intestine, Ki=kidney, Li=liver, Lu=lung, He=heart, Sp=spleen, Mu=muscle. Scale bars represent 100 Âµm.
Supplementary Figure S4 from Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966
Authors: Lee Tae Jin , Nair Mitra , Banasavadi-Siddegowda Yeshavanth , Liu Joseph , Nallanagulagari Tejaswini , Jaime-Ramirez Alena Cristina , Guo Jeffrey Yunhua , Quadri Haroon , Zhang Jianying , Bockhorst Kurt H. , Aghi Manish K. , Carbonell W. Shawn , Kaur Balveen , Yoo Ji Young
Published: April 2023

Supplementary Figure S4 shows that oHSV infection increases ITGB1 expression.